Agentix (AGTX) Total Non-Current Liabilities (2016 - 2019)
Agentix's (AGTX) quarterly Total Non-Current Liabilities came in at $85000.0 in Q3 2019, up 85.8% YoY from $45747.0 in Q3 2018, and down 21.8% on a QoQ basis from $108690.0 in Q2 2019.
Agentix (AGTX) Total Non-Current Liabilities (2016 - 2019) Analysis & Trends
Agentix (AGTX) has 4 years of Total Non-Current Liabilities data on file, last reported at $85000.0 in Q3 2019.
- Quarterly Total Non-Current Liabilities rose 85.8% year-over-year to $85000.0 in Q3 2019, while the trailing twelve-month figure through Aug 2019 was $85000.0 (up 85.8% YoY) and the FY2019 annual result came in at $85000.0, up 85.8% from the prior year.
- Total Non-Current Liabilities eased to $85000.0 in Q3 2019, from $108690.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $108690.0 in Q2 2019 to a low of $3689.0 in Q3 2016.
- A 4-year average of $58637.4 and a median of $66728.0 in 2018 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2017 — Total Non-Current Liabilities jumped 1727.87% — and 2018, when it tumbled 59.0%.
- Tracing AGTX's Total Non-Current Liabilities over 4 years: stood at $15621.0 in 2016, then soared by 429.06% to $82645.0 in 2017, then decreased by 19.26% to $66728.0 in 2018, then climbed by 27.38% to $85000.0 in 2019.
- The last three Total Non-Current Liabilities figures came in at $85000.0 (Q3 2019), $108690.0 (Q2 2019), and $97709.0 (Q1 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 9.32 Bn |
| 10 | Agentix | 801,339.00 | 801,301.00 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Aug 31, 2019 | 85,000.00 |
| May 31, 2019 | 108,690.00 |
| Feb 28, 2019 | 97,709.00 |
| Nov 30, 2018 | 66,728.00 |
| Aug 31, 2018 | 45,747.00 |
| May 31, 2018 | 19,766.00 |
| Feb 28, 2018 | 102,860.00 |
| Nov 30, 2017 | 82,645.00 |
| Aug 31, 2017 | 67,430.00 |
| May 31, 2017 | 48,215.00 |
| Feb 28, 2017 | 18,186.00 |
| Nov 30, 2016 | 15,621.00 |
| Aug 31, 2016 | 3,689.00 |